Using Medical Evidence to Design Pharmacy Benefits Improving Care and Bending the Cost Curve

- Cost growth remains the principle focus of health reform discussions among employers
- Despite unequivocal evidence of clinical benefit, Americans systematically underuse high-value prescription drugs
- Slowdown in healthcare costs may have negative health implications
- Attention should turn from how much to how well we spend our health care dollars



Motivation for "Clinically Nuanced" Benefit Design

- Ideally consumer cost-sharing levels would be set to encourage clinically appropriate use
- "One-size-fits-all" cost-sharing fails to acknowledge the differences in clinical value among prescription drugs
- Consumer cost sharing is increasing





"I can't believe you had to spend a million dollars to show that if you make people pay more for something, they will buy less of it."

Barbara Fendrick (my mother)



Impact of Increases in Consumer Cost-Sharing on Health Care Utilization The New York Times

A growing body of evidence concludes that increases in consumer costsharing leads to a reduction in the use of essential services, worsens health disparities, and in some cases leads to greater overall costs



Goldman D. *JAMA*. 2007;298(1):61–9. Trivedi A. *NEJM*. 2008;358:37(2010;362(4):320-8.. Chernew M. J Gen Intern Med 23(8):1131–6.

What is a surprise is that amid these complex issues, one policy it

Solutions Are Needed to Enhance Efficiency

 Targeted solutions are necessary to better allocate health expenditures on the clinical benefit - not the price or profitability – of services



A New Approach: Clinical Nuance

1. Services differ in clinical benefit produced



2. Clinical benefits from a specific service depend on:



Using Medical Evidence to Design Benefits Value-Based Insurance Design

- Sets consumer cost-sharing level on clinical benefit not acquisition price of the service
 - Reduce or eliminate financial barriers to high-value clinical services
- Successfully implemented by hundreds of public and private payers
- Accumulating evidence
- Broad multi-stakeholder and bipartisan political support



Putting Innovation into Action: Create Broad Multi-Stakeholder Support

- HHS
- CBO
- SEIU
- MedPAC
- Brookings Institution
- The Commonwealth Fund
- NBCH
- PCPCC
- Partnership for Sustainable Health Care
- Families USA
- AHIP

- National Governor's Assoc.
- US Chamber of Commerce
- Bipartisan Policy Center
- Kaiser Family Foundation
- NBGH
- National Coalition on Health Care
- Urban Institute
- RWJF
- IOM
- PhRMA
- AARP



Putting Innovation into Action: Translating Research into Policy

- Patient Protection and Affordable Care Act
- Medicare
- State Health Reform
- HSA-qualified HDHPs

HSA-qualified HDHPs: Too Much "Skin in the Game"?

- More than 25% of employers offer HDHPs
- 85% of enrollees in the individual marketplace purchased either silver or bronze HDHP plans
- Higher out-of-pocket costs hinder the use of evidence-based drugs(even when exempt from the deductible)
- HDHP enrollees with chronic diseases are more likely to go without care due to cost or experienced financial hardship due to medical bills



Barriers to V-BID in HSA-qualified HDHPs

- IRS guidance specifically exclude services meant to treat "an existing illness, injury or condition" from the definition of preventive care
- Many well-established quality metrics require the entire deductible to be met before coverage begins
- 90% of employers support expanding deductibleexempt definition to include chronic disease care






V-BID HDHP Hybrid with "Smarter Deductibles": High Value Health Plan

HVHP allows evidence-based, services that manage chronic disease to be deductible-exempt:

- Lower premiums than PPOs and HMOs; slight premium increase over existing HDHPs
- >40 million likely enrollees
- Vehicle to avoid "Cadillac tax"
- Substantially lower aggregate healthcare expenditures on a population level





Applying V-BID to Specialty Medications

- Impose no more than modest costsharing on high-value services
- Reduce cost-sharing in accordance with patient- or disease-specific characteristics
- Relieve patients from high costsharing after failure on a different medication
- Use cost-sharing to encourage patients to select high-performing providers and settings

Fendrick et al. Center for Value Based Insurance Design. http://bit.ly/1kMP2cq Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design

A. Mark Fendrick, MD Jason Buxbaum, MHSA Kimberly Westrich, MA



CENTER FOR VALUE-BASED INSU

Using Clinical Nuance to Align Payer and Consumer Incentives: As Easy as Peanut Butter and Jelly

• Many "supply side" initiatives are restructuring provider incentives to move from volume to value





AJAC. 2014;2(3);10.

Using Clinical Nuance to Align Payer and Consumer Incentives: As Easy as Peanut Butter and Jelly

- "Supply side" initiatives are restructuring provider incentives to move from volume to value
- Unfortunately, "demand-side" initiatives are moving consumers in the opposite direction





AJAC. 2014;2(3);10.

Using Clinical Nuance to Align Payer and Consumer Incentives: As Easy as Peanut Butter and Jelly

- "Supply side" initiatives are restructuring provider incentives to move from volume to value
- Unfortunately, "demand-side" initiatives are moving consumers in the opposite direction







AJAC. 2014;2(3);10.







www.vbidcenter.org @um_vbid vbidcenter@umich.edu

